AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Isofol Medical

Major Shareholding Notification Oct 20, 2022

3063_iss_2022-10-20_41c3a235-a766-43fc-80d9-ab235fd796dd.pdf

Major Shareholding Notification

Open in Viewer

Opens in native device viewer

Issuer Isofol Medical AB (publ)

Holder

Avanza Bank Holding AB för Försäkringsaktiebolaget Avanza Pension

Instrument
------------ --
Instrument Aktier
Before the transaction
Shares Data not given*
Voting rights Data not given*
Transaction
Reason for major shareholding notification Share loan
Date 19/10/2022
Limit for number of shares 5 %
Limit for number of votes 5 %
After the transaction
Quantity
Shares 9,300,873
Directly held voting rights 0
Indirectly held voting rights 9,300,873
Percentage
Directly held shares 5.7585 %
Directly held voting rights 0 %
Indirectly held voting rights 5.7585 %

Resulting distribution of total holdings

Percentage of voting
rights:
Number of underlying
shares:
Shares 5.7585 % 9,300,873
Instruments - FITA Ch. 4, section 2, first
paragraph, line 2
Instruments - FITA Ch. 4, section 2,
first paragraph, line 3
- Physically settled
- Cash settled 0.27116 % 437,966
Total 6.02966 % 9,738,839

Group total holdings

Voting rights 9,738,839 Percentage of voting rights 6.02966

Notes (other relevant informations according to law)

Aktierna, samt övriga instrument enligt LHF 4 kap, 2§ första stycket 1 och finansiella instrument enligt LHF 4 kap. 2§ första stycket 3 innehas av Försäkringsaktiebolaget Avanza Pension som är ett helägt dotterbolag till Avanza Bank Holding AB (publ). Angivet gränsvärde har överskridits på grund av retur av utlånade aktier.

Published

20/10/2022 10:41

Contact

Name Marie Andersson

Email [email protected]

*Source of information has chosen not to submit the data

[email protected] Tfn 08-408 980 37 Fax 08-24 39 25

Talk to a Data Expert

Have a question? We'll get back to you promptly.